| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040313992 |
| P356 | DOI | 10.2165/00003088-200645010-00001 |
| P698 | PubMed publication ID | 16430308 |
| P2093 | author name string | Sven Björkman | |
| P2860 | cites work | Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. | Q50945299 |
| Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. | Q51521960 | ||
| The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. | Q51539980 | ||
| Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. | Q51558252 | ||
| Population pharmacokinetics of midazolam in neonates. | Q51617618 | ||
| Alfentanil pharmacokinetics in cardiac surgical patients. | Q51640888 | ||
| Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. | Q51689576 | ||
| Sex, age and alfentanil pharmacokinetics. | Q51709593 | ||
| The disposition of alfentanil in neonates with respiratory distress. | Q51719976 | ||
| Influence of age on the pharmacokinetics of alfentanil. Gender dependence. | Q51724242 | ||
| Pharmacokinetics of midazolam in critically ill neonates. | Q51742733 | ||
| Pharmacokinetics of alfentanil during and after a fixed rate infusion. | Q51753059 | ||
| A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. | Q51768137 | ||
| The pharmacokinetics of alfentanil in children. | Q51782174 | ||
| Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. | Q51798529 | ||
| Pharmacokinetics of alfentanil in chronic renal failure. | Q51798549 | ||
| Alfentanil kinetics in the elderly | Q51840884 | ||
| Effect of age, gender, and obesity on midazolam kinetics. | Q51841259 | ||
| Pharmacokinetics of the infusion of alfentanil in man. | Q51851040 | ||
| Pharmacokinetics of alfentanil in man | Q51860233 | ||
| Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood | Q51861642 | ||
| Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. | Q54159719 | ||
| Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients | Q68900561 | ||
| Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit | Q70212573 | ||
| Cytochrome P450 3A: ontogeny and drug disposition | Q33813327 | ||
| Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period | Q34062843 | ||
| Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein | Q34124678 | ||
| Developmental pharmacology--drug disposition, action, and therapy in infants and children | Q34247047 | ||
| Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. | Q34456322 | ||
| How important are gender differences in pharmacokinetics? | Q34660699 | ||
| Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. | Q34836887 | ||
| Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. | Q34982129 | ||
| Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein | Q34994066 | ||
| Role of P-glycoprotein in pharmacokinetics: clinical implications | Q35029495 | ||
| Drug metabolism and disposition in children | Q35152977 | ||
| Dose estimation for children | Q35598801 | ||
| Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs | Q35827012 | ||
| Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants | Q35827686 | ||
| Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance | Q36750350 | ||
| Protein binding predictions in infants | Q37361786 | ||
| Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. | Q40576581 | ||
| Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. | Q40876694 | ||
| Gender effects in pharmacokinetics and pharmacodynamics | Q40923059 | ||
| Delayed ontogenesis of CYP1A2 in the human liver | Q41061622 | ||
| Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth | Q41099327 | ||
| Pharmacokinetics of drugs used in critically ill adults | Q41706103 | ||
| Clinical pharmacokinetics of alfentanyl (author's transl) | Q42241511 | ||
| Expression of CYP2D6 in developing human liver | Q43721677 | ||
| Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model | Q43824833 | ||
| A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans | Q43830739 | ||
| The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration | Q43836988 | ||
| Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. | Q44068570 | ||
| Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity | Q44351175 | ||
| The Pharmacokinetics of Alfentanil (R39209): A New Opioid Analgesic | Q44352177 | ||
| Developmental expression of the major human hepatic CYP3A enzymes | Q44585544 | ||
| Developmental expression of human hepatic CYP2C9 and CYP2C19. | Q44666457 | ||
| Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone | Q44962627 | ||
| Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis | Q45146008 | ||
| Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes | Q45158721 | ||
| Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. | Q47331599 | ||
| A size standard for pharmacokinetics. | Q47332170 | ||
| Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation | Q48251932 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-11 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods? | |
| P478 | volume | 45 |
| Q35949142 | A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. |
| Q51013612 | A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. |
| Q48010349 | A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach |
| Q42320775 | Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? |
| Q38011809 | Allometric extrapolation of factors VII, VIII and IX clearance in children from adults |
| Q37198909 | Characterizing metabolic inhibition using electrochemical enzyme/DNA biosensors |
| Q54266810 | Clinical aspects of tacrolimus use in paediatric renal transplant recipients. |
| Q30497854 | Clinical pharmacology in the adolescent oncology patient |
| Q27006333 | Clinical pharmacology of midazolam in neonates and children: effect of disease-a review |
| Q89046883 | Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice |
| Q47227162 | Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. |
| Q35179536 | Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. |
| Q38086777 | Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations |
| Q42283823 | Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. |
| Q37781110 | Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance |
| Q37127683 | Developmental pharmacology: neonates are not just small adults... |
| Q46750587 | Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain |
| Q38187000 | Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings |
| Q37666706 | Drug Development for Pediatric Populations: Regulatory Aspects |
| Q34099716 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. |
| Q90474677 | External Validation of a Pharmacokinetic Model of Propofol for Target-Controlled Infusion in Children under Two Years Old |
| Q36627208 | Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations |
| Q37067431 | Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma |
| Q33574651 | In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3 |
| Q38000252 | Neonatal pharmacology: extensive interindividual variability despite limited size |
| Q28078794 | Paediatric pharmacokinetics and drug doses |
| Q82287870 | Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4 |
| Q34737758 | Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy |
| Q38563371 | Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. |
| Q37550561 | Pharmacokinetics in special populations |
| Q38688708 | Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. |
| Q38758820 | Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development |
| Q38838930 | Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance. |
| Q36036400 | Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers |
| Q43060269 | Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. |
| Q24647832 | Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model |
| Q51099069 | Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. |
| Q38599526 | Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models |
| Q36653892 | Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models |
| Q38016504 | Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach |
| Q38365645 | Prediction of drug clearance in children |
| Q38367747 | Prediction of drug clearance in children: a review of different methodologies |
| Q38256006 | Prediction of drug clearance in children: an evaluation of the predictive performance of several models |
| Q33998916 | Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children |
| Q51796989 | Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. |
| Q46477241 | Response to the comments of Professors Anderson & Holford |
| Q43285207 | Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. |
| Q47148724 | Scientific Opinion on Bisphenol A: evaluation of a study investigating its neurodevelopmental toxicity, review of recent scientific literature on its toxicity and advice on the Danish risk assessment of Bisphenol A |
| Q47306662 | The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients |
| Q88968527 | The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling |
| Q35062145 | The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine |
| Q37492046 | The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults |
| Q37804767 | The pharmacology of anaesthetics in the neonate |
| Q28751735 | To scale or not to scale: the principles of dose extrapolation |
| Q36024899 | Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance |
Search more.